Compare OGE & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGE | BIO |
|---|---|---|
| Founded | 1902 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.0B |
| IPO Year | N/A | N/A |
| Metric | OGE | BIO |
|---|---|---|
| Price | $44.34 | $294.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $47.11 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 1.6M | 230.9K |
| Earning Date | 02-18-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | ★ 29.01 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $3,294,800,000.00 | $2,557,500,000.00 |
| Revenue This Year | $6.45 | $1.50 |
| Revenue Next Year | $4.37 | $2.23 |
| P/E Ratio | $17.65 | ★ N/A |
| Revenue Growth | ★ 18.03 | N/A |
| 52 Week Low | $40.80 | $211.43 |
| 52 Week High | $47.33 | $350.00 |
| Indicator | OGE | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 40.17 |
| Support Level | $42.93 | $298.09 |
| Resistance Level | $44.54 | $307.41 |
| Average True Range (ATR) | 0.74 | 9.71 |
| MACD | 0.11 | -0.46 |
| Stochastic Oscillator | 91.33 | 23.16 |
OGE Energy is a holding company for Oklahoma Gas & Electric, a regulated utility with electricity generation, transmission, and distribution service for 900,000 customers in Oklahoma and western Arkansas. In December 2021, OGE divested its 25.5% stake in Enable Midstream Partners, an oil and gas services company it created in 2013 through a unit exchange merger with Energy Transfer. OGE sold its 95.4 million limited partner units of Energy Transfer throughout 2022. OGE sold its retail gas business in 1928 and no longer has any gas operations.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.